Tous Actualités
Suivre
Abonner LifeWatch AG

LifeWatch AG

EANS-Adhoc: LifeWatch and Magnacare sign an agreement for the NiteWatch Home Sleep Testing service (with document)

Un document

--------------------------------------------------------------------------------
  ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
  distribution. The issuer is solely responsible for the content of this
  announcement.
--------------------------------------------------------------------------------
Company Information/LifeWatch AG

17.10.2011

Neuhausen am Rheinfall/Switzerland - LifeWatch AG (SIX Swiss Exchange: LIFE),
the leading wireless remote cardiac and medical patient monitoring service
provider in the U.S., today reports that it has successfully negotiated an
important contract for its NiteWatch service with the New York insurance
company Magnacare Administrative Services. This agreement will extend coverage
to the 850´000 lives insured by Magnacare.

You will find a PDF-version of this press release at the end of the message.

Acceptance of the NiteWatch Home Sleep Testing service for diagnosing
obstructive sleep apnea (OSA) is steadily on the rise in the U.S. healthcare
market. LifeWatch has been able to demonstrate to Magnacare Administrative
Services, an important regional East Coast commercial carrier, of the
advantages of the NiteWatch service. Patients insured by Magnacare will now
receive coverage for the NiteWatch service. The LifeStar ACT monitoring
services are already contacted by Magnacare, which covers 850,000 lives mainly
in New York and New Jersey.

The NiteWatch service is designed to diagnose OSA, which is characterized by
the temporary suspension of breathing during sleep. OSA is associated with an
increased risk of cardiovascular disease, stroke, high blood pressure,
arrhythmias, diabetes, and many serious accidents due to fatigue and sleepiness.
An estimated 38 million individuals in the U.S. suffer from OSA yet less than
one out of seven have been diagnosed correctly. Failure to diagnose is in part
due to the fact that patients are required to perform the test in a sleep lab,
which frequently have long wait times for a lab room. Patients are also
discomforted by sleeping in a strange environment, which can often adversely
affect test results.

Due to the growing recognition of the need for home sleep testing as a bona
fide alternative to sleep labs, the NiteWatch Home Sleep Testing service, is
becoming a diagnostic solution for many payors. Medicare already decided in
January 2009 to provide coverage for the Home Sleep Testing Service.

"Once Medicare decided to provide coverage for Home Sleep Testing in early
2009, private insurance companies began to follow suit. Magnacare, an important
East Coast commercial carrier, recognized the benefits of the NiteWatch
service. NiteWatch represents an important step for us toward more
diversification," stated Dr. Yacov Geva, Chairman and CEO of LifeWatch AG.
"Furthermore our NiteWatch service will contribute to better quality of life
for our patients thanks to earlier and more accurate detection which enables
more appropriate treatment options."


About LifeWatch AG:

LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on SIX Swiss
Exchange (LIFE), Switzerland, is the leading healthcare technology and solution
company, specializing in advanced telehealth systems and wireless remote
patient monitoring services. LifeWatch services cater to individuals, ranging
from high-risk and chronically ill patients, to consumers of health and
wellness products. LifeWatch has subsidiaries in the United States, the
Netherlands, Japan, the United Kingdom, Switzerland and Israel. LifeWatch AG is
the parent company of LifeWatch Services Inc., a leading US-based cardiac
monitoring service provider, and manufacturer of telecardiology products.
LifeWatch is also introducing a new program for Home Sleep Testing of
Obstructive Sleep Apnea (OSA) patients under the brand name NiteWatch. For
additional information, please visit www.lifewatch.com.

Sign-up for customized email alerts and documentation requests is available at
http://production.investis.com/lifewatch/alert-service/

This press release includes forward-looking statements. All statements other
than statements of historical facts contained in this press release, including
statements regarding future results of operations and financial position,
business strategy and plans and objectives for future operations, are forward-
looking statements. The words "believe," "may," "will," "estimate," "continue,"
"anticipate," "intend," "expect" and similar expressions are intended to
identify forward-looking statements. LifeWatch AG has based these forward-
looking statements largely on current expectations and projections about future
events and financial trends that it believes may affect the financial
condition, results of operations, business strategy, short term and long term
business operations and objectives, and financial needs. These forward-looking
statements are subject to a number of risks, uncertainties and assumptions. In
light of these risks, uncertainties and assumptions, the forward-looking events
and circumstances described may not occur and actual results could differ
materially and adversely from those anticipated or implied in the forward-
looking statements. All forward-looking statements are based only on data
available to LifeWatch AG at the time of the issue of this press release.
LifeWatch AG does not undertake any obligation to update any forward-looking
statements contained in this press release as a result of new information,
future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND
SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR PUBLICATIONS WITH A
GENERAL CIRCULATION IN THE UNITED STATES. THIS PRESS RELEASE DOES NOT
CONSTITUTE AN OFFER OF SECURITIES OF LIFEWATCH AG OR ANY OF ITS SUBSIDIARIES
FOR SALE IN THE UNITED STATES OR AN INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY
SECURITIES OF LIFEWATCH AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN
ADDITION, THE SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN
REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD
OR DELIVERED WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT REGISTRATION
UNDER OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE
UNITED STATES SECURITIES LAWS.  ANY PUBLIC OFFERING OF SECURITIES TO BE MADE IN
THE UNITED STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED
FROM LIFEWATCH AG OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED
INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL STATEMENTS
OF THE ISSUER.

Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/SWWwwWGh

Further inquiry note:
Sensus Investor and Public Relations GmbH, Zürich:
Tel +41 43 366 55 11 | Fax +41 43 366 55 12 | Email  lifewatch@sensus.ch

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/SWWwwWGh


issuer:      LifeWatch AG
             Rundbuckstrasse 6
             CH-8212 Neuhausen am Rheinfall
phone:       +41 52 632 00 50
FAX:         +41 52 632 00 51
mail:         users@lifewatch.com
WWW:      www.lifewatch.com
sector:      Healthcare Providers
ISIN:        CH0012815459
indexes:     SPI, SPIEX
stockmarkets: Open Market / XETRA: Frankfurt, free trade: Berlin, Main Standard:
             SIX Swiss Exchange 
language:   English

Plus de actualités: LifeWatch AG
Plus de actualités: LifeWatch AG